Patent · US Active

Treatment of cancer with TOR kinase inhibitors

US11166950B2 · kind B2 · utility

0Cited by

37References

5Claims

0Family size

Assignee

Signal Pharmaceuticals, LLC · US

Inventors

Shuichan Xu · San Diego, US
Kristen Mae Hege · Burlingame, US
Heather Raymon · San Diego, US
Rama Krishna Narla · San Diego, US
Rajesh Chopra · San Ramon, US

Key dates

Filing date	Feb 20, 2018
Grant date	Nov 9, 2021
Priority date	—
Expiry date	Feb 20, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.